Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. APGE
5. USO
6. MU
7. HOOD
8. DFTX
9. GOOGL
10. ABBV

Go back to Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance

Haemonetics (HAE) Strong Sell Rating Removed at Off Wall Street

April 28, 2015 11:11 AM EDT

Haemonetics's (NYSE: HAE) Strong Sell recommendation was removed at Off Wall Street after the company reported Q4 results and guidance, according to sources. Analysts noted FY16 guidance implies revenue and EPS growth.

... More

Barrington Research Downgrades Haemonetics (HAE) to Market Perform

April 28, 2015 9:38 AM EDT

Barrington Research downgraded Haemonetics (NYSE: HAE) from Outperform to Market Perform with a price target of $44.00. The change follows Q4 results and guidance.

Analyst Michael Petusky, "While we like many aspects of the Haemonetics story, particularly longer term, we do not see the... More

Haemonetics (HAE) PT Lifted at Jefferies Despite FX Hit

April 28, 2015 8:38 AM EDT

Jefferies analyst Anthony Petrone reiterated a Buy rating and bumped his price target on Haemonetics (NYSE: HAE) to $48.00 (from $45.00) following Q4 results. The analyst said while FX was unavoidable the underlying trends support a rebound in FY16.

Petrone commented, "HAE... More